Open AccessPITX2 and PANCR DNA methylation predicts overall survival in patients with head and neck squamous cell carcinoma
Author(s) -
Verena Sailer,
Emily A. Holmes,
Heidrun Gevensleben,
Diane Goltz,
F Dröge,
Luka de Vos,
Alina Franzen,
Friederike Schröck,
Friedrich Bootz,
Glen Kristiansen,
Andreas Schröck,
Dimo Dietrich
Publication year - 2016
Publication title -
oncotarget
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.373
H-Index - 127
ISSN - 1949-2553
DOI - 10.18632/oncotarget.12417
Subject(s) - dna methylation , medicine , head and neck squamous cell carcinoma , methylation , oncology , head and neck cancer , cancer research , head and neck , basal cell , overall survival , esophageal squamous cell carcinoma , carcinoma , cancer , biology , dna , genetics , surgery , gene , gene expression
Squamous cell carcinoma of the head and neck region (HNSCC) is a common malignant disease accompanied by a high risk of local or distant recurrence after curative-intent treatment. Biomarkers that allow for the prediction of disease outcome can guide clinicians with respect to treatment and surveillance strategies. Here, the methylation status of PITX2 and an adjacent lncRNA (PANCR) were evaluated for their ability to predict overall survival in HNSCC patients.